专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08853149B2 Integrin interaction inhibitors for the treatment of cancer 有权
标题翻译：用于治疗癌症的整联蛋白相互作用抑制剂
公开(公告)号：US08853149B2
公开(公告)日：2014-10-07
申请号：US13636010
申请日：2011-03-21
申请人： Lori Hazlehurst , Mark McLaughlin , Priyesh Jain , William S. Dalton
发明人： Lori Hazlehurst , Mark McLaughlin , Priyesh Jain , William S. Dalton
IPC分类号： A61K38/00 , C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K38/08 , A61K45/06
摘要： Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
摘要翻译：使用β-转角启动子的整联蛋白相互作用抑制剂在本文中描述。通过施用治疗有效量的整联蛋白相互作用抑制剂，这些肽可用于治疗癌症如多发性骨髓瘤。数据显示整联蛋白相互作用抑制剂与抗增殖剂如多柔比星，SAHA，三氧化二砷和依托泊苷协同或加成相互作用。

2. 发明申请

US20130065837A1 INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER 有权
公开(公告)号：US20130065837A1
公开(公告)日：2013-03-14
申请号：US13636010
申请日：2011-03-21
申请人： Lori Hazlehurst , Mark Mclaughlin , Priyesh Jain , William S. Dalton
发明人： Lori Hazlehurst , Mark Mclaughlin , Priyesh Jain , William S. Dalton
IPC分类号： A61K38/12 , C12N5/09 , C07K7/54 , A61P35/00
CPC分类号： C07K7/06 , A61K38/00 , A61K38/08 , A61K45/06
摘要： Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

3. 发明授权

US08227434B1 Materials and methods for treating oncological disorders 有权
标题翻译：用于治疗肿瘤疾病的材料和方法
公开(公告)号：US08227434B1
公开(公告)日：2012-07-24
申请号：US10983009
申请日：2004-11-04
申请人： William S. Dalton , Lori Hazlehurst , Qing Chen
发明人： William S. Dalton , Lori Hazlehurst , Qing Chen
IPC分类号： A61K31/70
CPC分类号： A61K31/7088 , C12N15/113 , C12N2310/14 , C12N2320/31
摘要： The subject invention pertains to materials and methods for treating oncological disorders. The subject invention also pertains to materials and methods for preventing or reducing the development by cancer cells of resistance to an anticancer therapy, such as chemotherapy, radiotherapy and/or immunotherapy. In one embodiment, a patient is treated with an agent that inhibits cholesterol synthesis or that prevents or reduces the increase in cholesterol synthesis observed in therapy-resistant cancer cells. In another embodiment, a patient is treated with an agent that increases the expression, activity, or amount of a Bim protein in a cell. In another embodiment, a patient is treated with an agent to inhibit or reduce cancer cell adhesion to extracellular matrices or stromal cells. In another embodiment, a patient is treated with an agent to inhibit expression of a gene of function of a protein of the FANC/BRCA pathway. In a further embodiment, a patient is treated with an agent to prevent or reduce the DNA crosslink repair function of a cell.
摘要翻译：本发明涉及用于治疗肿瘤疾病的材料和方法。本发明还涉及用于预防或减少癌细胞对化疗，放射治疗和/或免疫治疗等抗癌治疗的抗性的发展的材料和方法。在一个实施方案中，患者用抑制胆固醇合成的药物或用于预防或减少在耐药性癌细胞中观察到的胆固醇合成的增加来治疗。在另一个实施方案中，用增加细胞中Bim蛋白的表达，活性或量的试剂治疗患者。在另一个实施方案中，用药剂治疗患者以抑制或减少癌细胞对细胞外基质或基质细胞的粘附。在另一个实施方案中，患者用药物治疗以抑制FANC / BRCA途径的蛋白质的功能基因的表达。在另一个实施方案中，用试剂治疗患者以预防或减少细胞的DNA交联修复功能。

4. 发明申请

US20080108552A1 HYD1 Peptides as Anti-Cancer Agents 失效
标题翻译： HYD1肽作为抗癌剂
公开(公告)号：US20080108552A1
公开(公告)日：2008-05-08
申请号：US11852177
申请日：2007-09-07
申请人： Lori Hazlehurst , William Dalton , Anne Cress , Kit Lam
发明人： Lori Hazlehurst , William Dalton , Anne Cress , Kit Lam
IPC分类号： A61K38/00 , A61P35/00 , C07H21/02 , C07K7/06 , C12N15/00 , C12N5/00
CPC分类号： G01N33/5011 , C07K7/06
摘要： The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention concerns a method of identifying modulators of peptide binding. Another aspect of the invention concerns a method for detecting CTC.
摘要翻译：本发明涉及HYD1肽的片段和变体; 编码肽的多核苷酸; 用多核苷酸遗传修饰的宿主细胞; 包含多核苷酸的载体; 含有这些肽，多核苷酸，载体或宿主细胞的组合物; 以及使用肽，多核苷酸，载体和宿主细胞作为体外或体内异常细胞生长的抑制剂的方法，例如用作治疗癌症如骨髓瘤的抗癌剂。本发明进一步包括增加化学疗法和放射治疗功效的方法，其包括向有需要的患者施用结合β1整联蛋白的药剂。在一个实施方案中，β1整联蛋白结合剂是HYD1肽或其功能片段或变体。另一方面，本发明涉及一种组合物（粘附陷阱），其包含固定在基底上的HYD1肽或其片段或变体的底物（也称为表面或载体），以及除去循环的方法通过使受试者的血液与固定的肽接触，从血液中获得肿瘤细胞（CTC）。本发明的另一方面涉及鉴定肽结合调节剂的方法。本发明的另一方面涉及一种检测CTC的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式